Lucence Diagnostics Presents Largest Genetic Study of Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome

November 2, 2018

Lucence Diagnostics presented the largest genetic study conducted on Vietnamese patients with hereditary breast and ovarian cancer at the Asia-Pacific Society of Human Genetics Meeting this week. This was a collaborative study with the National Cancer Centre Singapore, Pasteur Clinic Da Nang and CarePlus Vietnam.

Breast cancer is the most common cancer in Vietnamese women. Relatively little is known about predisposing breast cancer genetic factors in less-well characterized populations in Southeast Asia. As breast cancer is the leading cancer in women, it is important to understand its causes in diverse populations.

This is the first multi-gene study to investigate the predisposing genetic factors for hereditary breast and ovarian cancers in Vietnamese patients. It involved 531 patients across Asia, including Vietnam, with a personal and/or family history of breast and ovarian cancer syndrome. The study found a higher prevalence of pathogenic BRCA mutations in Vietnamese women than expected. This highlights the importance of deep understanding of population genetics, for better patient treatment and clinical outcomes.

The study was conducted through Lucence’s LumiBRCA™ testing that detects mutations predisposing to cancer in patients. Lucence supports better healthcare for women globally in its mission of zero avoidable cancer deaths.

Need Help?